HK109097A - Composition comprising heparin and rapamycin - Google Patents

Composition comprising heparin and rapamycin

Info

Publication number
HK109097A
HK109097A HK109097A HK109097A HK109097A HK 109097 A HK109097 A HK 109097A HK 109097 A HK109097 A HK 109097A HK 109097 A HK109097 A HK 109097A HK 109097 A HK109097 A HK 109097A
Authority
HK
Hong Kong
Prior art keywords
rapamycin
heparin
composition
mammal
preventing
Prior art date
Application number
HK109097A
Other languages
English (en)
Inventor
Robert Dempster Mitchell
Stephen Skwish
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/874,895 external-priority patent/US5288711A/en
Priority claimed from GB929217630A external-priority patent/GB9217630D0/en
Application filed by American Home Prod filed Critical American Home Prod
Publication of HK109097A publication Critical patent/HK109097A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK109097A 1992-04-28 1997-06-26 Composition comprising heparin and rapamycin HK109097A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/874,895 US5288711A (en) 1992-04-28 1992-04-28 Method of treating hyperproliferative vascular disease
GB929217630A GB9217630D0 (en) 1992-08-19 1992-08-19 Method of treating hyperproliferative vascular disease

Publications (1)

Publication Number Publication Date
HK109097A true HK109097A (en) 1997-08-22

Family

ID=26301459

Family Applications (1)

Application Number Title Priority Date Filing Date
HK109097A HK109097A (en) 1992-04-28 1997-06-26 Composition comprising heparin and rapamycin

Country Status (15)

Country Link
EP (1) EP0568310B1 (de)
JP (1) JP2550277B2 (de)
KR (1) KR100284210B1 (de)
AT (1) ATE135226T1 (de)
AU (1) AU670937B2 (de)
BR (1) BR9301667A (de)
CA (1) CA2094858C (de)
DE (1) DE69301754T2 (de)
DK (1) DK0568310T3 (de)
ES (1) ES2085720T3 (de)
GR (1) GR3019380T3 (de)
HK (1) HK109097A (de)
HU (1) HU215388B (de)
SG (1) SG43030A1 (de)
TW (1) TW224051B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994016706A1 (en) 1993-01-28 1994-08-04 Neorx Corporation Therapeutic inhibitors of vascular smooth muscle cells
US5620687A (en) * 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
DE69435342D1 (de) 1993-07-19 2011-05-05 Angiotech Pharm Inc Anti-Angiogene Mittel und Verfahren zu deren Verwendung
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
WO1995014023A1 (en) * 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5618837A (en) * 1995-06-07 1997-04-08 Zymogenetics, Inc. PDGF antagonists III
DK0833828T3 (da) 1995-06-09 2003-03-17 Novartis Ag Rapamycinderivater
EP0835115B1 (de) * 1995-06-30 2004-05-06 ZymoGenetics, Inc. 4-(2-(n-(-2-carboxamidoindole)aminiethyl)-benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
IT1289815B1 (it) 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US7445792B2 (en) 2003-03-10 2008-11-04 Abbott Laboratories Medical device having a hydration inhibitor
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
DE60026513T2 (de) * 1999-05-27 2006-10-05 Biocompatibles Uk Ltd., Farnham Lokale arzneistoffabgabe
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
WO2001087375A1 (en) * 2000-05-12 2001-11-22 Cordis Corporation Delivery devices for treatment of vascular disease
AU2005202474B2 (en) * 2000-05-12 2007-09-06 Cardinal Health 529, Llc Delivery devices for treatment of vascular disease
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
AU1129902A (en) * 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
MXPA03002871A (es) 2000-09-29 2004-12-06 Johnson & Johnson Dispositivos medicos recubiertos.
US6746773B2 (en) 2000-09-29 2004-06-08 Ethicon, Inc. Coatings for medical devices
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
ES2243556T3 (es) 2000-10-16 2005-12-01 Conor Medsystems, Inc. Dispositivo medico expandible para proporcionar un agente beneficioso.
US8182527B2 (en) 2001-05-07 2012-05-22 Cordis Corporation Heparin barrier coating for controlled drug release
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
WO2004010900A1 (en) * 2002-07-25 2004-02-05 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
US7438925B2 (en) * 2002-08-26 2008-10-21 Biovention Holdings Ltd. Drug eluting coatings for medical implants
US8791171B2 (en) 2003-05-01 2014-07-29 Abbott Cardiovascular Systems Inc. Biodegradable coatings for implantable medical devices
CA2559741A1 (en) 2004-03-26 2005-10-20 Surmodics, Inc. A medical article having a bioactive agent-releasing component with photoreactive groups
EP2329852A1 (de) 2004-03-26 2011-06-08 SurModics, Inc. Zusammensetzung und Verfahren zur Herstellung von biokompatiblen Oberflächen
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
CN101583384A (zh) 2006-07-03 2009-11-18 汉莫堤克股份有限公司 持久使血管开的活性物释放医药产品的制造、方法和使用
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
EP2491962A1 (de) 2007-01-21 2012-08-29 Hemoteq AG Medizinprodukt zur Behandlung von Verschlüssen von Körperdurchgängen und zur Prävention drohender Wiederverschlüsse
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US20090074831A1 (en) * 2007-09-18 2009-03-19 Robert Falotico LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS
US8921642B2 (en) 2008-01-11 2014-12-30 Massachusetts Eye And Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
ES2550634T3 (es) 2009-07-10 2015-11-11 Boston Scientific Scimed, Inc. Uso de nanocristales para un balón de suministro de fármaco
US10080821B2 (en) 2009-07-17 2018-09-25 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
WO2013022458A1 (en) 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating

Also Published As

Publication number Publication date
CA2094858A1 (en) 1993-10-29
TW224051B (de) 1994-05-21
EP0568310B1 (de) 1996-03-13
AU3713693A (en) 1993-11-04
HU9301216D0 (en) 1993-07-28
DE69301754T2 (de) 1996-08-08
HUT64231A (en) 1993-12-28
HU215388B (hu) 1998-12-28
BR9301667A (pt) 1993-11-03
JP2550277B2 (ja) 1996-11-06
JPH0680573A (ja) 1994-03-22
GR3019380T3 (en) 1996-06-30
ATE135226T1 (de) 1996-03-15
AU670937B2 (en) 1996-08-08
CA2094858C (en) 2004-06-15
DK0568310T3 (da) 1996-07-29
SG43030A1 (en) 1997-10-17
ES2085720T3 (es) 1996-06-01
KR100284210B1 (ko) 2001-03-02
EP0568310A1 (de) 1993-11-03
DE69301754D1 (de) 1996-04-18
KR940005280A (ko) 1994-03-21

Similar Documents

Publication Publication Date Title
HK109097A (en) Composition comprising heparin and rapamycin
SG47639A1 (en) Method of treating hyperproliferative vascular disease
IL108455A0 (en) Vascular and coronary stents
SG47786A1 (en) Method of treating crohn's disease ulcerative colitis or ulcerative proctitis
EP0608853A3 (de) Einrichtung zur vasculären Dilatation und Katheter.
AU1791895A (en) Method of preventing hyperproliferative vascular disease
ZA947973B (en) Antimicrobial treatment of textile materials
DE69426740D1 (de) Antibakterielle Gefässprothese und chirurgisches Nahtmaterial
ZA943522B (en) Medical stent
ZA961183B (en) Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
GB9512452D0 (en) A prosthetic vascular graft
DE69419804D1 (de) Ortsfeste Gefässprothese
GB9207808D0 (en) Vascular graft apparatus
EP0472215A3 (en) Water-repellent and oil-repellent treatment agent
GB9311784D0 (en) Vascular bioartificial organ
KR0139221B1 (en) Use of chlormethiazole in the prevention and/or treatment of neurodegeneration
GB2233898B (en) Agent for preventing and treating opacity of the lens
GB9325612D0 (en) Vascular grafts
GB9300426D0 (en) Vascular grafts
GB2297263B (en) Vascular prostheses
CS9000785A2 (en) Soaking and pre-washing agent
EP0349654A4 (en) Agent for prophylaxis and treatment of pancreatic disease or the like
GB9201316D0 (en) Pin and track retainer
LTIP1423A (en) Device for treatment of gullet stricture
EP0932406A4 (de) Verfahren zur behandlung oder vorbeugung der interstitiellen blasenentzündung

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20130426